A Virtual Event delivered in the GMT time zone
Clinical Trials Europe
Stay ahead with pioneering insights on COVID-19, decentralized clinical trials, patient recruitment and engagement strategies, real world evidence, the Clinical Trials Regulation, digital health and beyond. Attend a session featuring a Labcorp Drug Development specialist and learn in-depth knowledge.
Bringing Pediatric DCTs to Europe and Beyond: How New Tools Promote Patient Engagement and Protocol Compliance
Wednesday, November 3, 2021 | 10:25 a.m. GMT | Stream: Decentralized Trials & Technology Day Two
In this talk you will learn:
- How DCTs are increasingly being implemented in Europe and other regions
- What tools are in most demand for European clinical trials
- How in-home visits kept a pediatric neuromuscular trial on-track during the COVID-19 pandemic
- How mobile apps and online tools can reduce the need for in-person site visits
- How to promote protocol compliance and patient engagement in pediatric & adolescent patient trials through gamification
Kurt Lumsden
Head, Global Operations, Mobile Clinical Services
Kurt Lumsden, RN, BS, MBA is a proven leader and clinician with extensive experience in the healthcare and clinical research sectors gained over 34 years in the US and UK, including operational and client account management roles with pharmaceutical, CRO, hospital, home care, eClinical technology and mobile clinical service organizations. He has broad therapeutic experience including but not limited to neuroscience, oncology, immunology, infectious disease, pulmonology, cardiology and rare disease. Kurt is a Registered Nurse in Illinois, holds a Bachelor of Science in Perfusion Technology from Rush University, Chicago, IL, a Bachelor of Arts in Healthcare Leadership from National-Louis University, Evanston, IL and an MBA from City University, Seattle, WA.
Kate Griffin
VP DCT Strategy & Enablement, Labcorp Drug Development
Kate Griffin has 26 years of life sciences consulting and CRO management experience, all with a focus on strategy, development and creation of new approaches. She is passionate about improving experiences for patients and sites and the opportunity to disrupt drug development. She is a problem solver and big picture thinker with a passion for the ability to use data and technology to change the way drugs are developed and delivered. She is the founder of a boutique management consulting firm focused in life sciences due diligence, management supplementation, strategy and organizational development.
Wednesday, November 3, 2021 | 12:20 p.m. GMT | Stream: Early Clinical Development – Stream Two: COVID-19 Learnings Day Two
If the pandemic continues there is still a critical need for potent SARS-CoV-2 treatments. Learn how Labcorp Drug Development was able to coordinate efforts and make use of innovative regulatory processes and adaptive protocol design elements to expedite study start up and conduct for a biotech company developing a new antiviral drug, to enable first human dose just 23 days after the first meeting between sponsor and CRO. Within nine weeks this promising new drug was ready for Phase II testing, instead of the standard eight months for a study conducted under standard timelines. How could you benefit from this approach?
Jim Bush, MBChB, PhD
Vice President, Medical Clinical Pharmacology Services
Dr Jim Bush earned his MBChB and PhD degrees from the University of Manchester, UK. After working in Early Clinical Development for a small Biotech for more than 7 years he joined Labcorp in 2011 and has since worked at the Labcorp Phase I unit in Leeds, UK as Principal Investigator for Phase I clinical trials, including First in Human studies. He manages the global Labcorp team of Clinical Pharmacology Physicians and is primarily responsible for the safety of Phase I clinical trial participants.
Diversity and Inclusion: Operational Approaches to Increasing the Diversity of Investigators and Patients
Wednesday, November 3, 2021 | 12:45 p.m. GMT | Stream: Patient Engagement – Operations Day Two
While increasing the diversity and inclusion of patients in studies represents a clear unmet need, the practical realities are less obvious. In this session, we will explore how to balance the need to pursue D&I objectives with the need to get trials underway, and demonstrate some of the solutions Labcorp is undertaking to continually expand diversity and inclusion in its global trials.
Melissa Harris
Director, Patient Recruitment & Engagement
Melissa has 21 years of industry experience with two years of Labcorp Drug Development tenure creating patient centric recruitment programs for all phases of studies including pediatric, rare and hard-to-reach patient populations. Melissa works to harness the benefits of applying innovative solutions toward successful patient recruitment campaigns while driving health literacy and patient-led trials to reduce study burden and facilitate the study into everyday life. Melissa also supports Labcorp Drug Development’s Voice of Patient program to drive patient insights into every step of the drug development paradigm.
Kristen Andrews
Senior Director, Site Centric Solutions
Kristen Andrews has over 25 years of experience in clinical trials. Starting as a Clinical Research Coordinator, her career has progressed through increasing levels of responsibility and leadership first at research sites and then in Site Partner programs at CROs. She is a passionate advocate for sites and is dedicated to advancing site relationships with their industry partners. Kristen is currently the Senior Director for Site Centric Solutions at Labcorp Drug Development.
Tales from the Front: Patient Equity and Engagement in Practice from Trial Design Through Execution
Thursday, November 4, 2021 | 14:05 p.m. GMT | Stream: Afternoon Plenary
Delivering patient equity by making trials more accessible to wider demographics around the world is becoming the critical next step in trail design. We will use case studies and stories from our clients to focus on how clinical trial models are evolving to deliver “the right patients” and keep them engaged during the trial. Our panel of speakers will cover patient recruitment, trial design, and post-approval access to new therapies.
Talley Mitchell
Senior Director, Patient Recruitment and Engagement
Talley Mitchell is Senior Director and Head of the Patient Recruitment and Engagement team at Labcorp Drug Development. She has more than 20 years of research experience and came to Labcorp Drug Development in 2012 as a clinical project manager. She is a graduate of the Labcorp Drug Development Rotational Program, where she held various roles within Clinical Development and Commercialization Services and gained broad drug development experience. For the past four years Talley has focused on utilizing Labcorp data and patient touchpoints to create innovative and differentiating patient recruitment strategies aimed at making clinical trials more accessible for all.
Talley has a B.A. in Psychology from Bethel University and a M.S. in Biomedical Sciences from Rosalind Franklin University of Medicine and Science.
Kate Griffin
VP DCT Strategy & Enablement
Kate Griffin has 26 years of life sciences consulting and CRO management experience, all with a focus on strategy, development and creation of new approaches. She is passionate about improving experiences for patients and sites and the opportunity to disrupt drug development. She is a problem solver and big picture thinker with a passion for the ability to use data and technology to change the way drugs are developed and delivered. She is the founder of a boutique management consulting firm focused in life sciences due diligence, management supplementation, strategy and organizational development.
Daniel Martin
VP, Global Laboratory and Extended Services
Daniel has over 22 years of Central Labs experience. His tenure has included both individual and leadership roles within the laboratory, project management, and global lab support & extended services teams. He currently has global oversight for the Clinical Trial Lab Support Teams, Extended Services Service Lines, and the Drug Development Dx testing activities. He is responsible for developing and executing the business strategies for these groups. Daniel earned a bachelor’s degree in Medical Technology from West Virginia University and an MBA from the University of Indianapolis.
Labcorp respects your privacy.